EGFR and non-small cell lung carcinoma: The first-generation EGFR TKIs, such as erlotinib and gefitinib, and the second-generation EGFR TKIs such as afatinib, have been widely used in the treatment of patients with advanced non-small cell lung cancer (NSCLC) [18,19,20].